We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Abiraterone acetate-associated QT prolongation and torsades de pointes: Postmarketing cases reported to FDA.
- Authors
McBride, Lauren; Woronow, Daniel; Nayernama, Afrouz; Christopher Jones, S
- Abstract
In the article, the authors present their study on abiraterone acetate-associated QT prolongation and torsades de pointes (TdP) as a clinical consequence of hypokalemia and the regulatory actions made by the U.S. Food and Drug Administration (FDA). Also cited are the use of abiterone acetate and androgen deprivation therapy (ADT) as standard treatments for metastatic prostate cancer, and the FDA Adverse Event Reporting System (FAERS) data used in the study.
- Subjects
ABIRATERONE acetate; LONG QT syndrome; METASTASIS; VENTRICULAR tachycardia; UNITED States. Food &; Drug Administration; HYPOKALEMIA; PROSTATE tumors
- Publication
Journal of Oncology Pharmacy Practice, 2021, Vol 27, Issue 5, p1315
- ISSN
1078-1552
- Publication type
Article
- DOI
10.1177/10781552211015794